Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration

This paper, which is a narrative review and mechanistic synthesis, not a clinical trial; links the biochemical receptor affinities of ibogaine with neurobiological processes that could support remyelination and metabolic homeostasis in neurological disorders.

It evaluates existing preclinical and translational evidence regarding ibogaine’s neurobiological effects.

Ibogaine has a broad multi-receptor pharmacological profile, including activity at:

• NMDA receptors

• Opioid receptors (including kappa)

• Sigma receptors

• Monoaminergic systems.

The authors propose that this multi-receptor activity may converge on neurorestorative pathways, rather than acting through a single mechanism. The review highlights evidence suggesting ibogaine may influence:

• Oligodendrocyte function and myelin-related processes

• Neuroplasticity signaling pathways

• Cellular metabolic regulation, including mitochondrial and energy-related mechanisms

  The paper discusses how disrupted myelination and metabolic dysfunction are common across several neuropsychiatric and neurological disorders, and proposes that ibogaine’s pharmacology could theoretically support:

  • Remyelination

  • Metabolic restoration

  • Broader neural repair processes

  The paper argues that ibogaine’s multi-receptor pharmacology may plausibly engage neurorestorative pathways related to myelin repair and metabolic normalization, but current evidence remains preliminary and primarily preclinical. The work is hypothesis-generating rather than confirmatory.

“Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ibogaine and relief of symptoms of neuropsychiatric conditions including substance use disorder, multiple sclerosis, and traumatic brain injury. Ibogaine has multi-receptor actions, but the neurobiological mechanisms underlying such putative effects is unknown.

Here we review and discuss the relevant literature, focusing on remyelination and metabolic restoration. We provide evidence that ibogaine upregulates markers of myelination following opioid administration; that conditions such as opioid use disorder, multiple sclerosis and traumatic brain injury are characterized by white matter pathology; that decreased myelination is related to dysregulated metabolic homeostasis, ischemia and hypoxia which may also play a role in these disorders.

We conclude that multi-receptor actions of ibogaine, especially its affinities for the NMDA, kappa opioid and sigma receptors, in turn account for reduction in excitotoxicity, metabolic regulation, lasting neuroplasticity and immunomodulation that facilitates neuronal repair and remyelination providing a rationale for future investigation of its use as a therapeutic agent for these common central nervous system disorders.”

Calvey T, Govender D, Owen G, et al. Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration. Acta Neuropsychiatrica. Published online 2026:1-36. doi:10.1017/neu.2026.10059 Read Paper

For more psychedelic news and research, visit the psychedelic health professional network homepage.